Preliminary Final Report and Annual Report YE 31 March 2026
Filed with ASX · · 70 pages · English
Summary by 6ix AI
The report highlights the promising data from the ACCENT trial, which shows improved patient outcomes when combining narmafotinib with standard chemotherapy. Additionally, the company has made strides in manufacturing capabilities and regulatory discussions, positioning itself for future clinical developments. Amplia also successfully raised funds to support ongoing research and development activities, enhancing its financial stability.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib
- Amplia Launches First Stage of Pivotal Narmafotinib Trial
- Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
- Amplia and ANZGOG announce Ovarian Cancer Study
- Accent Trial Mature Data Presented at International Conference
Later from Amplia Therapeutics
- Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer
- Amplia Announces Changes to Board’s Leadership Roles
- Amplia Announces Appointment of Brett Carter to Board
- Amplia Announces Publication of New FAK Inhibitor Patent Application
- Notice of Annual General Meeting/Proxy Form
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics